Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab in Psoriatic Arthritis (Open-Label Extension)
NCT07223138Phase 3Enrolling by invitation
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 3 trial of sonelokimab in psoriatic arthritis (PsA), sponsored by MoonLake Immunotherapeutics. Started Nov 2025; status: enrolling by invitation.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT07223138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223138.